ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder

Ryan Marino, Jeanmarie Perrone, Lewis S. Nelson, Timothy J. Wiegand, Evan S. Schwarz, Paul M. Wax, Andrew I. Stolbach

Research output: Contribution to journalArticle

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)307-309
Number of pages3
JournalJournal of Medical Toxicology
Volume15
Issue number4
DOIs
StatePublished - Oct 1 2019

Keywords

  • Buprenorphine
  • Opioid agonist therapy
  • Opioid use disorder
  • Waiver
  • X-waiver

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Marino, R., Perrone, J., Nelson, L. S., Wiegand, T. J., Schwarz, E. S., Wax, P. M., & Stolbach, A. I. (2019). ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder. Journal of Medical Toxicology, 15(4), 307-309. https://doi.org/10.1007/s13181-019-00728-9